Biogen Inc Stock Performance
| BIIB Stock | USD 132.59 1.61 1.23% |
On a scale of 0 to 100, Biogen holds a performance score of 7. The firm shows a Beta (market volatility) of 1.38, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biogen will likely underperform. Please check Biogen's maximum drawdown, semi variance, and the relationship between the sortino ratio and potential upside , to make a quick decision on whether Biogen's price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Biogen Inc are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak forward indicators, Biogen may actually be approaching a critical reversion point that can send shares even higher in August 2025. ...more
Actual Historical Performance (%)
One Day Return 1.23 | Five Day Return 2.49 | Year To Date Return (11.61) | Ten Year Return (57.15) | All Time Return 4.1 K |
Last Split Factor 3:1 | Last Split Date 2001-01-18 |
1 | New Data for Nusinersen Underscore Biogens Commitment to Advancing Clinical Research to ... | 06/27/2025 |
2 | Biogen Inc Trading 4.67 percent Higher on Jul 1 | 07/01/2025 |
3 | Biogen Insiders Sold US1.8m Of Shares Suggesting Hesitancy | 07/09/2025 |
4 | Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer | 07/15/2025 |
5 | Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer | 07/16/2025 |
6 | Cwm LLC Increases Stake in Biogen Inc. | 07/17/2025 |
7 | Edgestream Partners L.P. Sells 3,285 Shares of Biogen Inc. | 07/18/2025 |
8 | Biogen to Highlight Scientific Progress Across Alzheimers Disease at the Alzheimers ... | 07/21/2025 |
9 | ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements DelveInsight | 07/22/2025 |
10 | The Myth of All-American Drugs and What Trumps Tariffs Miss About Pharma Supply Chains | 07/23/2025 |
| Begin Period Cash Flow | 1 B | |
| Total Cashflows From Investing Activities | -799.2 M |
Biogen Relative Risk vs. Return Landscape
If you would invest 11,912 in Biogen Inc on April 26, 2025 and sell it today you would earn a total of 1,347 from holding Biogen Inc or generate 11.31% return on investment over 90 days. Biogen Inc is currently generating 0.1953% in daily expected returns and assumes 1.9957% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than Biogen, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biogen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biogen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biogen Inc, and traders can use it to determine the average amount a Biogen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0979
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BIIB | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.0 actual daily | 17 83% of assets are more volatile |
Expected Return
| 0.2 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.1 actual daily | 7 93% of assets perform better |
Based on monthly moving average Biogen is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biogen by adding it to a well-diversified portfolio.
Biogen Fundamentals Growth
Biogen Stock prices reflect investors' perceptions of the future prospects and financial health of Biogen, and Biogen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biogen Stock performance.
| Return On Equity | 0.0919 | ||||
| Return On Asset | 0.0543 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 23.22 B | ||||
| Shares Outstanding | 146.53 M | ||||
| Price To Earning | 14.83 X | ||||
| Price To Book | 1.13 X | ||||
| Price To Sales | 1.98 X | ||||
| Revenue | 9.68 B | ||||
| Gross Profit | 7.43 B | ||||
| EBITDA | 2.83 B | ||||
| Net Income | 1.63 B | ||||
| Cash And Equivalents | 4.91 B | ||||
| Cash Per Share | 34.10 X | ||||
| Total Debt | 6.63 B | ||||
| Debt To Equity | 0.52 % | ||||
| Current Ratio | 2.49 X | ||||
| Book Value Per Share | 115.90 X | ||||
| Cash Flow From Operations | 2.88 B | ||||
| Earnings Per Share | 10.12 X | ||||
| Market Capitalization | 19.43 B | ||||
| Total Asset | 28.05 B | ||||
| Retained Earnings | 19.26 B | ||||
| Working Capital | 1.93 B | ||||
| Current Asset | 8.73 B | ||||
| Current Liabilities | 3.42 B | ||||
About Biogen Performance
By analyzing Biogen's fundamental ratios, stakeholders can gain valuable insights into Biogen's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biogen has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biogen has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 388.71 | 201.06 | |
| Return On Tangible Assets | 0.14 | 0.08 | |
| Return On Capital Employed | 0.10 | 0.08 | |
| Return On Assets | 0.06 | 0.06 | |
| Return On Equity | 0.10 | 0.10 |
Things to note about Biogen Inc performance evaluation
Checking the ongoing alerts about Biogen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biogen Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 93.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from medcitynews.com: The Myth of All-American Drugs and What Trumps Tariffs Miss About Pharma Supply Chains |
- Analyzing Biogen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biogen's stock is overvalued or undervalued compared to its peers.
- Examining Biogen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biogen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biogen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biogen's stock. These opinions can provide insight into Biogen's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |